FDA Shifts to Single Pivotal Trial Standard

What Is Changing in FDA Drug Approval Standards?

For decades, the FDA's interpretation of the Federal Food, Drug, and Cosmetic Act has rested on the principle of "substantial evidence" of effectiveness, traditionally established through two adequate and well-controlled clinical trials. The two-trial requirement was intended to guard against false-positive findings and ensure reproducibility before a medicine reached the public. Under the new direction, regulators may increasingly accept a single pivotal study when accompanied by additional confirmatory evidence such as mechanistic data, real-world evidence, or robust biomarker support.

The shift builds on flexibility already embedded in the FDA Modernization Act of 1997, which formally allowed approval based on one adequate and well-controlled investigation plus confirmatory evidence in appropriate circumstances. In practice, this pathway has been used most often in oncology, rare diseases, and life-threatening conditions where running two large trials is impractical or unethical. The new policy direction signals that the agency intends to apply this flexibility more broadly across therapeutic areas.

Why Is the FDA Moving Toward a Single-Study Pathway?

Drug development is among the longest and most expensive endeavors in medicine. Industry analyses estimate that bringing a single new molecular entity from discovery to approval can take more than a decade and cost in excess of $2 billion when accounting for failed candidates. Proponents of a one-trial standard argue that high-quality, sufficiently powered single studies — especially those with robust statistical thresholds and large effect sizes — can provide the same level of certainty as two smaller trials, while sparing patients from prolonged waits for promising therapies.

The change also aligns U.S. practice more closely with several international regulators, including the European Medicines Agency, which has long accepted single-trial submissions for select indications. Supporters point to advances in trial design, including adaptive protocols, master protocols, and the use of real-world data, as tools that strengthen the inferential power of any individual trial. Combined with post-marketing surveillance through systems such as Sentinel, regulators argue that uncertainty at approval can be addressed through ongoing safety monitoring.

What Are the Risks of Approving Drugs on Less Evidence?

Independent reviewers and patient safety advocates have raised concerns that lowering the evidentiary threshold could expose patients to therapies whose benefits have not been independently replicated. Historical examples — including drugs approved through accelerated pathways that were later withdrawn after confirmatory studies failed — illustrate how single-trial findings can sometimes overstate clinical benefit. Reproducibility of results across distinct study populations has long been considered a cornerstone of pharmacologic evidence.

The change also places greater weight on post-marketing commitments, real-world evidence, and pharmacovigilance to detect rare adverse events and confirm long-term efficacy. Critics caution that compliance with post-approval study requirements has historically been uneven, and that patients and clinicians may be left to navigate uncertainty about a drug's true value. Balancing speed of access against confidence in benefit remains the central tension in any major regulatory reform.